Immunovaccine Announces Positive Clinical Data from Its Collaborative Combination Immunotherapy Trial in Advanced Ovarian Cancer
Data From First Dosing Cohort Show a 70% Disease Control Rate – Including 30% of Patients with Partial Responses – and Demonstrate a Tolerable Safety Profile
Initial results from ten evaluable patients in the DPX-Survivac plus 100 mg epacadostat dosing cohort demonstrate a disease control rate of 70%, including partial responses (PR, defined as ≥30% decrease in tumor lesion size) in 30% of the patients (three out of ten). To date, the combination also exhibited a well-tolerated safety profile, with the majority of adverse events (AEs) reported as Grade 1 and Grade 2, and only one potential treatment-related AE.
“Individuals with recurrent ovarian cancer, in particular, have not yet benefited from immunotherapy treatment breakthroughs in the way that those with other hard-to-treat cancers have,” said Frederic Ors, Chief Executive Officer of
Blood tests indicated that the majority of treated patients exhibited targeted T cell activation. Tumor biopsies and analyses thus far have supported the reported mechanism of action (MOA) of this immunotherapy combination, with DPX-Survivac triggering T cell infiltration into the tumor. This T cell activation was also correlated with tumor regression.
“These first data from this trial are consistent with our prior clinical findings, which indicated that DPX-Survivac could deliver best-in-class T cell activation,” continued Mr. Ors. “We believe that these results support the theory that our T cell activation can lead to tumor regressions, which is critical for advancing immunotherapy treatments for many types of cancer.”
About the Phase 1b Trial
The Phase 1b trial is a single-arm, non-randomized, open label, uncontrolled, safety and efficacy study for patients with advanced, platinum-sensitive and resistant ovarian cancer. Investigators completed enrollment of ten evaluable patients for the study’s first dosing cohort, which consists of 100 mg epacadostat twice daily (BID), DPX-Survivac, and low-dose cyclophosphamide.
In the first dosing cohort, investigators observed:
- A 30% overall response rate, with three out of ten PRs
- Two of the patients exhibiting PRs have completed one year of treatment with responses ongoing at 12 and 14 months, respectively
- Four patients (40%) had stable disease
- Two of the patients exhibiting stable disease are still enrolled in the trial, with one of those patients showing a 21% tumor reduction
- A 70% disease control rate (defined as the total number of patients achieving complete response, partial response, and stable disease)
At the time of data cut-off, there were also preliminary data on the first three evaluable patients in the second dosing cohort evaluating the combination of 300 mg BID epacadostat, DPX-Survivac, and low-dose cyclophosphamide. From the first three evaluable patients, two showed stable disease, with one patient showing tumor regression of approximately 25%. The second dosing cohort is ongoing and is expected to enroll 16 to 40 patients in total.
“The activation of T cells is the hallmark of DPX-Survivac’s mechanism of action, and, we believe, this initial data shows, for the first time, a significant number of tumor regressions in a combination therapy clinical trial centered on T cell activation technology,” said Mr. Ors. “We are of the opinion that these data provide clinical proof-of-concept that significantly de-risks our development strategy for both our partners and shareholders, while potentially bringing future benefits to patients in need. We are looking forward to building on this solid foundation to accelerate the Company’s growth.”
Conference Call and Webcast Information
About Ovarian Cancer
According to the
Ovarian cancer has a significant impact globally as well.
DPX-Survivac consists of survivin-based peptide antigens formulated in Immunovaccine’s proprietary DepoVax™ delivery platform. DPX-Survivac is thought to work by eliciting a cytotoxic T cell immune response against cells presenting survivin peptides. Survivin, recognized by the
Immunovaccine Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of them will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the completion of clinical trials and receipt of all regulatory approvals.
T: (312) 961-2502 E: email@example.com
Pierre Labbé, Chief Financial Officer
T: (902) 492-1819 E: firstname.lastname@example.org
O: (415) 513-1284
T: (415) 515-4572 E: email@example.com
Source: Immunovaccine Inc.